• Corpus ID: 20991783

Improved Synthesis Process of Ambrisentan and Darusentan

@article{Li2015ImprovedSP,
  title={Improved Synthesis Process of Ambrisentan and Darusentan},
  author={J. Li and Ling Tian},
  journal={Chemical engineering transactions},
  year={2015},
  volume={46},
  pages={43-48}
}
  • J. LiL. Tian
  • Published 20 December 2015
  • Chemistry
  • Chemical engineering transactions
2-hydroxy-3-phenoxy-3, 3-diphenylpropinate (5) was prepared from benzophenone via Darzens, methanolysis and hydrolysis reaction. The compound (5) was salified with (S)-dehydroabietylamine (7) and diasterotropic resolution was carried out to provide the key intermediate (S)-2-hydroxy-3-methoxy-3, 3-diphenylpropionic acid (6). Compound (6) was condensed with 2-methylsulfonyl-4, 6-dimethylpyrimidine and 2-methoxysulfonyl4, 6-dimethylpyrimidine to afford ambrisentan (1) and darusentan (7… 

Figures and Tables from this paper

Highly Enantioselective Production of Chiral Secondary Alcohols with Candida zeylanoides as a New Whole Cell Biocatalyst

Results indicate that C. zeylanoides P1 is a promising biocatalyst for the synthesis of chiral alcohols in industry.

References

SHOWING 1-10 OF 18 REFERENCES

Improved Synthesis of Ambrisentan

Benzophenone,as a starting material,went through a series of reactions,such as Darzens,methanolysis and hydrolysis to give 2-hydroxy-3-methoxy-3,3-diphenylpropionic acid(5).The latter reacted with

Synthesis of darusentan,an ET_A selective endothelin receptor antagonist

Objective: To synthesize darusentan, an ET_A selective endothelin receptor antagonist. Methods: Using diphenyl ketone as a starting material, the target compound was synthesized via several steps,

Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists.

A novel class of endothelin-A receptor ligands was discovered by high-throughput screening which can be synthesized in a short sequence and show a long duration of action.

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.

Role of Ambrisentan in the Management of Pulmonary Hypertension

A significant advantage of ambrisentan is the lack of any clinically important drug interactions with warfarin and sildenafil, which are frequently used by patients being treated for PAH.

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

Preliminary results suggest that pulmonary hypertension is associated with the increased expression of endothelin-1 in vascular endothelial cells, suggesting that the local production of endethelin- 1 may contribute to the vascular abnormalities associated with this disorder.

[Updated clinical classification of pulmonary hypertension].

The main change was to withdraw persistent pulmonary hypertension of the newborn (YPPH) from Group 1 because this entity carries more differences than similarities with other PAH subgroups and PPHN is now designated number 1.